Veno‐Arterial Extracorporeal Life Support in Heart Transplant and Ventricle Assist Device Centres. Meta‐analysis

Aims Because reported mortality on veno‐arterial (V‐A) extracorporeal life support (ECLS) substantially varies between centres, the aim of the current analysis was to assess the outcomes between units performing heart transplantation and/or implanting ventricular assist device (HTx/VAD) vs. non‐HTx/...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ESC Heart Failure 2021-04, Vol.8 (2), p.1064-1075
Hauptverfasser: Kowalewski, Mariusz, Zieliński, Kamil, Gozdek, Mirosław, Raffa, Giuseppe Maria, Pilato, Michele, Alanazi, Musab, Gilbers, Martijn, Heuts, Sam, Natour, Ehsan, Bidar, Elham, Schreurs, Rick, Delnoij, Thijs, Driessen, Rob, Sels, Jan Willem, Poll, Marcel, Roekaerts, Paul, Pasierski, Michał, Meani, Paolo, Maessen, Jos, Suwalski, Piotr, Lorusso, Roberto
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aims Because reported mortality on veno‐arterial (V‐A) extracorporeal life support (ECLS) substantially varies between centres, the aim of the current analysis was to assess the outcomes between units performing heart transplantation and/or implanting ventricular assist device (HTx/VAD) vs. non‐HTx/VAD units in patients undergoing V‐A ECLS for cardiogenic shock. Methods and results Systematic search according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses was performed using PubMed/MEDLINE databases until 30 November 2019. Articles reporting in‐hospital/30‐day mortality and centre's HTx/VAD status were included. In‐hospital outcomes and long‐term survival were analysed in subgroup meta‐analysis. A total of 174 studies enrolling n = 13 308 patients were included with 20 series performed in non‐HTx/VAD centres (1016 patients, 7.8%). Majority of patients underwent V‐A ECLS for post‐cardiotomy shock (44.2%) and acute myocardial infarction (20.7%). Estimated overall in‐hospital mortality was 57.2% (54.9–59.4%). Mortality rates were higher in non‐HTx/VAD [65.5% (59.8–70.8%)] as compared with HTx/VAD centres [55.8% (53.3–58.2%)], P 
ISSN:2055-5822
2055-5822
DOI:10.1002/ehf2.13080